BIMONTHLY INTERNAL ASSESSMENT - FEBRUARY

Case:1

50 year man, he presented with the complaints of

Frequently walking into objects along with frequent falls since 1.5 years

Drooping of eyelids since 1.5 years

Involuntary movements of hands since 1.5 years 

Talking to self since 1.5 years 


More here: 


Case presentation  links: 

 

a). What is the problem representation of this patient and what is the anatomical localization for his current problem based on the clinical findings?

Problem presentation:

A 50 year old male diabetic farmer by occupation who had an episode of seizure 10 yrs back presented with c/o frequently walking into objects along with frequent falls,Drooping of eyelids,Involuntary movements of hands & Talking to self since 1.5 years was diagnosed with progressive supranuclear palsy.

Anatomical localization:

Brain

B/l ptosis : weakness of levator palbebral superioris

(without loss of frowning)

self talk : frontal lobe

vertical gaze palsy:

The centres and pathway for vertical gaze palsy is:

supranuclear / nuclear / infranuclear (eg.nmj disorders)

Intact doll's eye, suggests a supranuclear lesion

b) What is the etiology of the current problem and how would you as a member of the treating team arrive at a diagnosis? Please chart out the sequence of events timeline between the manifestations of each of his problems and current outcomes. 

Etiology:

Progressive supranuclear palsy: etiology is likely due to accumulation of 'tau' protein in brain

Sequence of events:

Seizures (10 years)

!

T2DM (2 years)

!

Sudden blurring of vision while riding bike -- RTA -- #left leg -- operated (2 years)

!

Frequently walking into objects along with frequent falls

Drooping of eyelids

Involuntary movements of hands

Talking to self (1.5 years) 

!

Stopped alcohol & tobacco consumption (1 year)

!

Non productive cough (8 months)

!

Non healing ulcer @ surgical site & hypokalemic periodic paralysis (7 months)

!

Hospital stay for 1 week - diagnosed as PSP & discharged with SYNDOPA 110 MG & QUETIAPINE

!

5 days later patient presented to casualty in a state of unresponsiveness GCS: 3/15 with h/o 2-3 episodes vomiting.

!

Another 2 episodes of generalized tonic seizures happened in casualty - symptomatic management given

!

Suddenly his saturations & heart rate went down with no peripheral pulsations and patient was intubated - CPR done according to 2015 AHA guidelines and was resuscitated.

!

Currently on mechanical ventilator ACMV



c) What is the efficacy of each of the drugs listed in his current treatment plan 

Quetiapine:

Quetiapine in the treatment of psychosis in Parkinson’s disease

https://pubmed.ncbi.nlm.nih.gov/17159457/

Syndopa:

https://www.nejm.org/doi/full/10.1056/nejmoa033447



The severity of parkinsonism increased more in the placebo group than in all the groups receiving levodopa: the mean difference between the total score on the parkinson's Disease Rating Scale (UPDRS) at baseline and at 42 weeks was 7.8 units in the placebo group, 1.9 units in the group receiving levodopa at a dose of 150 mg daily, 1.9 in those receiving 300 mg daily, and –1.4 in those receiving 600 mg daily (P<0.001

https://clinicaltrials.gov/ct2/show/NCT03761030


Case:2

Patient was apparently asymptomatic 2 years back then he developed weakness in the right upper and lower limb, loss of speech.


More here: 


Case presentation  links: 


a). What is the problem representation of this patient and what is the anatomical localization for his current problem based on the clinical findings?

Problem presentation:

60 year old male non diabetic & non hypertensive who had a history of CVA 2 years back now presented with c/o SOB,pedal edema,decreased urine output & generalized weakness since 2 months.

Anatomical localization: 

Heart - HFrEF secondary to CAD


b) What is the etiology of the current problem and how would you as a member of the treating team arrive at a diagnosis? Please chart out the sequence of events timeline between the manifestations of each of his problems and current outcomes. 


Etiology:

Coronary artery disease (?Cardio cerebral infarction)

Ecg showing:
1)normal axis
2)pathological Q waves from v1 to v6
3)poor R wave progression
suggest a CAD probably involving LAD and LCX territory 


Sequence of events:

CVA (2 years)
!
SOB, pedal edema, decreased urine output & generalized weakness (2 months)
!
Started on triple therapy
!
Outcome: Symptomatically improved and discharged


c) What is the efficacy of each of the drugs listed in his current treatment plan 




Salt and fluid restriction

https://pubmed.ncbi.nlm.nih.gov/23787719/#:~:text=Conclusion%3A%20Individualized%20salt%20and%20fluid,Quality%20of%20life%3B%20Salt%20restriction.

Ninety-seven stable patients in NYHA class II-IV, on optimal medication, with previous signs of fluid retention, treated with either >40 mg (NYHA III-IV) or >80 mg (NYHA II-IV) of furosemide daily were randomized to either individualized salt and fluid restriction or information given by the nurse-led heart failure clinics, e.g. be aware not to drink too much and use salt with caution, and followed for 12 weeks. Fluid was restricted to 1.5 L and salt to 5 g daily, and individualized dietary advice and support was given.
Results After 12 weeks, significantly more patients in the intervention than in the control group improved on the composite endpoint (51% vs. 16%; P < 0.001), mostly owing to improved NYHA class and leg oedema. No negative effects were seen on thirst, appetite, or QoL

Benfomet as thiamine replacement in alcoholic patients

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550087/

Aldactone(spironolactone)

https://www.aafp.org/afp/2001/1015/p1393.html
Based on earlier work suggesting a benefit of therapy,2 the Randomized Aldactone Evaluation Study (RALES) was undertaken to evaluate the role of spironolactone when used in addition to standard therapy for CHF.


Case:3

52 year old male , shopkeeper by profession  complains of  SOB, cough  ,decrease sleep and appetite since 10 days and developed severe hyponatremia soon after admission. 

Morehere:


Case presentation video:


a) What is the problem representation of this patient and what is the anatomical localization for his current problem based on the clinical findings?

Problem presentation:

A 52 year old male shopkeeper known diabetic & hypertensive presented with c/o SOB,cough,decreased sleep&appetite diagnosed with dimorphic anemia & dyselectrolytemia

Anatomical localization: 

Anemia - Bone marrow

Hyponatremia - ? SIADH (lung pathology)


b) What is the etiology of the current problem and how would you as a member of the treating team arrive at a diagnosis? Please chart out the sequence of events timeline between the manifestations of each of his problems and current outcomes. 

Etiology:

Dimorphic anemia secondary to ? Nutritional 
Hyponatremia secondary to free fluid (dilutional) - poor sugar control (hyperglycemia)

I would rather give lasix and avoid giving fluids as he is having heart failure and hyponatremia which further aggrevates by giving free fluid.


Sequence of events:


T2DM & HTN
!
SOB
Cough
Decreased sleep and appetite (1 year)
!
SOB
Cough
Decreased sleep and appetite (10 days)
!
Admitted
!
Dyselectrolytemia
!
Treated conservatively & discharged


c) What is the efficacy of each of the drugs listed in his current treatment plan especially for his hyponatremia? What is the efficacy of Vaptans over placebo? Can one give both 3% sodium as well as vaptan to the same patient?  

No role in giving monocef & metrogyl

Vaptans:


a) Reference
b) Typology of study		a) Vaptan
b) Population
c) Number of patients		a) Interventation
b) Time
c) Main Outcome		ResultsObservations

  1. Gheorghiade M (Circulation 2003). (26)

  2. double-blind, multicentric, RCCT.

  1. Tolvaptan

  2. Hyponatremia in chronic HF.

  3. n=254 patients:

    • - n=191 tolvaptan (n=64: 30 mg n=64: 45 mg n=63: 60 mg).

    • - n=63 placebo.

  1. fixed doses of 30, 45, 60 mg/die without fluidic restriction and with stable furosemide doses.

  2. 25 days.

  3. Primary efficacy variable: change in body weight at day 1 vs baseline.

A decrease in body weight and an increase in urine output doses-related (p<0.001 for all treated vs placebo).
Decrease in edema and normalization of s[Na+] in the tolvaptan group but not in the placebo group.
Not significant changes in HR, AP, s[K+], renal function.

  • -A significant number of patients had only mild CHF and modest volume overload.

  • -Necessity of further studies with NYHA-status stratification.

  • -Focused only on diuretic properties of tolvaptan witout mentioning neurohormonal effects.



4) Please mention your individual learning experiences from this month.

  • A case of ? Broncho-alveolar carcinoma--Lung biopsy - turned out to be organizing pneumonia
  • A case of Celiac disease--response to gluten free diet with superimposed giardiasis
  • A case of Budd chiari syndrome
  • A case of primary PAH
  • Cardio cerebral infarction
  • A case of ASD (?ostium secundum)
  • A case of severe PAH secondary to PTB--lung fibrosis--cor pulmonale
  • A case of VSD closure which again become defective
  • Rapidly filling ascites
  • Renal transplant prospects

Comments

Post a Comment

Popular posts from this blog

THESIS

Image
TOPIC: PREDICTORS OF OUTCOMES IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION AND HEART FAILURE ADMITTED TO A RURAL TERTIARY CARE HOSPITAL PROBLEM STATEMENT: HEART FAILURE is one of the leading cause of death at present all over the world. Inspite of the recent advances and extensive research being done in medical field we are unable to find the exact etiology and predictors of mortality and morbidity in many of the patients with HEART FAILURE and the current mode of treatment is only symptomatic. In a rural setup with limited resources: How far we can eliminate the diagnostic and therapeutic uncertainties that persist in a patient with heart failure and what best we can do to improve their outcomes. INTRODUCTION: Inspite of having advancement in field which helps in diagnosing pulmonary hypertension, it remains the disease that takes lot of time for diagnosis from the presence of first symptom, many patients are diagnosed only in advanced stage of disease. 1 Normal pressure in pulmon...
Read more

BIMONTHLY INTERNAL ASSESSMENT - MAY 2021

Image
Section : 1  Please go through the patient data in the links below and answer the following questions: 1) Pulmonology (10 Marks)  A) Link to patient details: https:// soumyanadella128eloggm. blogspot.com/2021/05/a-55- year-old-female-with- shortness-of.html Questions: 1) What is the evolution of the symptomatology in this patient in terms of an event timeline and where is the anatomical localization for the problem and what is the primary etiology of the patient's problem? Symptomatology & event time line: SOB  Grade-II  on & off since 20 Years (exacerbations once in a year) ! Increased frequency & severity of exacerbations since 12 Years ! T2DM since 8 Years ! Anemia 5 yrs back treated with iron sucrose ! Generalized weakness & SOB Grade-II since 30 days ! HTN since 20 days ! Pedal edema & Facial puffiness since 15 days ! SOB Grade-IV & decreased urine output since 2 days Anatomical localization:  Lungs - COPD - SOB Grade- II C...
Read more

BIMONTHLY INTERNAL ASSESSMENT - DECEMBER

Image
1) A 55 year old man with Recurrent Focal Seizures Detailed patient case report here:  http://ushaindurthi. blogspot.com/2020/11/55-year- old-male-with-complaints-of. html 1. What is the problem representation of this patient and what could be the anatomical site of lesion ? A 55 year old male construction worker with T2DM who is a chronic alcoholic & smoker came with c/o weakness of right upper limb with involuntary movements of both right UL & LL secondary to ? right temporal lobe epileptogenic focus. 2. Why are subcortical internal capsular infarcts more common that cortical infarcts? subcortical infarcts are caused by occlusion of a penetrating artery from a large cerebral artery, most commonly from the Circle of Willis. These penetrating arteries arise at sharp angles from major vessels and are thus, anatomically prone to constriction and occlusion.  So subcortical infarcts are more common than cortical infarcts. https://www.ncbi.nlm.nih.gov/books/NBK534206/#:~:te...
Read more